한글목차

세계 생물학적 제제 시장 규모는 2023년 4,529억 달러에서 예측 기간 동안 12.7%의 연평균 복합 성장률(CAGR)로 2028년 말에는 8,234억 달러 규모로 성장할 것으로 예상됩니다.

치료용 단백질 부문은 2023년 2,485억 달러에서 2028년 말에는 4,704억 달러 규모로 성장할 것으로 예상되며, 같은 기간 동안 13.6%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 전망됩니다. 세포 및 유전자 치료 부문은 2023년 604억 달러에서 2028년 말 1,194억 달러 규모로 14.6%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

세계의 생물학적 제제 시장을 조사했으며, 시장 및 기술 배경, 시장 영향요인 및 시장 기회 분석, 시장 규모 추이 및 예측, 각 부문별/지역별 상세 분석, 기술 동향, ESG 전망, 경쟁 구도, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 요약 및 하이라이트

• 시장 개요

제3장 시장 및 기술 배경

• 바이오의약품 산업 구조
• 바이오테크놀러지 기원
• 대형 제약회사 관여
• 생물학적 제제 개요
• 생물학적 제제 제조
• 바이오의약품 제조 공정
• 제제 프로세스
• 치료용 단백질 제조을 위한 발현 시스템
• 미생물 제조 대장균 이점
• 포유류 세포 치료용 단백질 제조
• 생물학적 제제 FDA 규제

제4장 시장 역학

• 시장 성장 촉진요인
• 개요
• 만성질환 유병률 상승
• 생물학적 제제 진보
• 세포 및 유전자 치료 방법 개발
• 감염증 및 만성질환 증가
• 시장 성장 억제요인
• 바이오시밀러 출현
• 생물학적 제제 고가의 비용
• 시장 기회
• 신흥 국가 기회

제5장 시장 내역 : 제품별

• 세계의 생물학적 제제 시장 : 제품별
• 치료용 단백질
• 백신
• 세포 및 유전자 치료
• 기타

제6장 시장 내역 : 용도별

• 세계의 생물학적 제제 시장 : 용도별
• 암
• 자가면역질환
• 미용
• 안질환
• 기타

제7장 시장 내역 : 소스별

• 세계의 생물학적 제제 시장 : 소스별
• 인간
• 동물
• 미생물
• 발효 세포
• 기타

제8장 시장 내역 : 지역별

• 세계의 생물학적 제제 시장 : 지역별
• 북미
• 유럽
• 아시아태평양
• 기타 지역
• GCC 국가
• 브라질
• 기타 나라

제9장 생물학적 제제 제조을 위한 최신 기술

• AcceTT 및 BacSec 기술
• 일회용 기술
• 세포 및 유전자 치료(CGT)
• 드기본 DNA(dbDNA)
• 동물 혈장 분리
• 잡종 세포 생성
• B세포 스크리닝
• 디스플레이 기술
• 신흥 생물학적 제제 발견·생성 기술
• 생물학적 제제 제조 기술 새로운 동향
• 신규 개발 사례 : 기업별
• Samsung Biologics
• AstraZeneca
• Genentech Inc.

제10장 바이오의약품 및 생물학적 제제 산업에서의 지속가능성 : ESG 관점

• 바이오의약품 제조 업계에서 ESG의 중요성
• ESG 평가와 지표 : 데이터 이해
• 바이오의약품 및 생물학적 제제 제조업계 ESG 실천
• BCC의 견해

제11장 M&A 및 벤처 자금조달 전망

• 인수합병(M&A) 분석
• 인수합병(M&A) 거래
• 생물학적 제제 주요 스타트업 기업
• 호조를 보이는 바이오테크놀러지 스타트업

제12장 FDA 승인 단클론항체

제13장 경쟁 구도

• Porter의 Five Forces 분석

제14장 기업 개요

• ABBVIE INC.
• AMGEN INC.
• BAXTER INTERNATIONAL INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• CSL LTD.
• DENDREON PHARMACEUTICALS LLC.
• ELI LILLY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GLAXOSMITHKLINE PLC
• GLYCOTOPE GMBH
• GRIFOLS S.A.
• JSC PHARMSTANDARD
• KEDRION S.P.A.
• LONZA
• MERCK & CO. INC.
• NOVARTIS AG
• OCTAPHARMA AG
• RELIANCE LIFE SCIENCES
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.

영문목차

Highlights:

The global market for biological therapeutic drugs is expected to increase from $452.9 billion in 2023 to $823.4 billion by the end of 2028, with a compound annual growth rate (CAGR) of 12.7% during the forecast period of 2023-2028.

Therapeutics and proteins market for biological therapeutic drugs is expected to increase from $248.5 billion in 2023 to $470.4 billion by the end of 2028, with a CAGR of 13.6% during the forecast period of 2023-2028.

Cell and gene therapy market for biological therapeutic drugs is expected to increase from $60.4 billion in 2023 to $119.4 billion by the end of 2028, with a CAGR of 14.6% during the forecast period of 2023-2028.

Report Scope:

The current report offers a detailed picture of the biologics market.

This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2028, as well as key market players.

This report details market shares for biologics based on product, source, application and geography. Based on product, the market is segmented into therapeutic proteins, cell and gene therapy, vaccines, and other segments. Based on application, the market is segmented into cancer, autoimmune conditions, aesthetics, eye disorders, and others. Based on source, the market is segmented into human, animal, micro-organism, fermented cell and others

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2022 as the base year, with forecasts for 2023 through 2028. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

• 38 data tables and 59 additional tables
• An overview of the global markets for biologic therapeutic drugs.
• Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.
• Estimate of the actual market size and revenue forecast, and a corresponding market share analysis by product type, therapeutic area and region.
• A discussion of the market's opportunities and challenges, as well as emerging technologies and regulations.
• Overview of the sustainability trends, with emphasis on consumer attitudes, companies' ESG scores, the future of ESG, case studies and the ESG practices of companies.
• A discussion of the technological means that the leading biopharmaceutical companies are using.
• Evaluation of the ongoing clinical trials and R&D activity for biologics production.
• A look at the key drugs on the market and recent approvals, sales statistics and past performance of the top selling biologics, as well as their patent expiries.
• Review of emerging technologies and patents.
• An overview of the competitive landscape, including a look at the major vendors' market shares, recent M&A activity, and venture funding outlook.
• Company profiles of major players within the industry, including Amgen Inc., Abbive Inc., Eli Lilly And Co., Novartis Ag, and Glaxosmithkline Plc

Table of Contents

Chapter 1 Introduction

• Introduction
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• What's New in this Update?
• Methodology
• Information Sources
• Geographic Breakdown
• Segmentation Breakdown

Chapter 2 Summary and Highlights

• Market Overview

Chapter 3 Market and Technology Background

• Biopharmaceutical Industry Structure
• Origins of Biotechnology
• Involvement of Large Pharmaceutical Companies
• Overview of Biologics
• Biologics Manufacturing
• Biopharmaceutical Manufacturing Process
• The Preparation Process
• Expression Systems for Therapeutic Protein Production
• Advantages of E. coli for Microbial Production
• Mammalian Cell Therapeutic Protein Production
• FDA Regulation of Biologics

Chapter 4 Market Dynamics

• Market Drivers
• Overview
• Rising Prevalence of Chronic Diseases
• Advancement in Biologics
• Development in Cell and Gene Therapy Methodology
• Increase in Infectious and Chronic Diseases
• Market Restraints
• Emergence of Biosimilars
• Expensive Cost of Biologics
• Market Opportunities
• Opportunities in Emerging Nations

Chapter 5 Market Breakdown by Product Segment

• Global Market for Biological Therapeutic Drugs by Product
• Therapeutic Proteins
• Vaccines
• Cell and Gene Therapy
• Others

Chapter 6 Market Breakdown by Application

• Global Market for Biological Therapeutic Drugs by Application
• Cancer
• Autoimmune Conditions
• Aesthetics
• Eye Disorder
• Others

Chapter 7 Market Breakdown by Source

• Global Market for Biological Therapeutic Drugs by Source
• Human
• Animal
• Microorganisms
• Fermented Cells
• Other Sources

Chapter 8 Market Breakdown by Region

• Global Market for Biological Therapeutic Drugs by Region
• North America
• Europe
• Asia-Pacific
• Rest of World
• GCC Countries
• Brazil
• Rest of World Countries

Chapter 9 Emerging Technology for Biologics Manufacturing

• Introduction
• AcceTT & BacSec Technologies
• Single-use Technologies
• Cell and Gene Therapy (CGT)
• Doggybone DNA (dbDNA)
• Animal Plasma Isolation
• Hybridoma Generation
• B Cell Screening
• Display Technologies
• Emerging Biologics Discovery and Generation Technologies
• Emerging Trends in Biologic Production Technologies
• Example of New Developments by Companies
• Samsung Biologics
• AstraZeneca
• Genentech Inc. (Member of Roche family)

Chapter 10 Sustainability in the Biopharmaceuticals and Biologics Industry: An ESG Perspective

• Importance of ESG in the Biopharmaceuticals Manufacturing Industry
• ESG Ratings and Metrics: Understanding the Data
• ESG Practices in the Biopharmaceuticals and Biologics Manufacturing Industry
• BCC Research Viewpoint

Chapter 11 M&A and Venture Funding Outlook

• M&A Analysis
• M&A Deals 2018-2023
• Top Biologic Drug Startups
• Flourishing Biotech Startups (2023)

Chapter 12 FDA Approved Monoclonal Antibodies, 1986-2023

Chapter 13 Competitive Landscape

• Porter's Five Forces Analysis
• Bargaining Power of Suppliers
• Bargaining Power of Buyers
• Threat of New Entrants
• Threat of Substitutes
• Competitive Rivalry/Degree of Competition

Chapter 14 Company Profiles

• ABBVIE INC.
• AMGEN INC.
• BAXTER INTERNATIONAL INC.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• CSL LTD.
• DENDREON PHARMACEUTICALS LLC.
• ELI LILLY AND CO.
• F. HOFFMANN-LA ROCHE LTD.
• GLAXOSMITHKLINE PLC
• GLYCOTOPE GMBH
• GRIFOLS S.A.
• JSC PHARMSTANDARD
• KEDRION S.P.A.
• LONZA
• MERCK & CO. INC.
• NOVARTIS AG
• OCTAPHARMA AG
• RELIANCE LIFE SCIENCES
• SANOFI
• TEVA PHARMACEUTICAL INDUSTRIES LTD.